SCHEMBL16201400

SCHEMBL16201400

CCCN(C)Cc1n[nH]cc1-c1ccc(OC(C)C)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 1/20 0.37
PRMT6 Q96LA8 2/20 0.36
PRMT1 Q99873 2/20 0.36
PRMT8 Q9NR22 2/20 0.36
PRMT3 O60678 1/20 0.36
CARM1 Q86X55 1/20 0.36
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
S1PR1 P21453 2/20 0.33
P2RX3 P56373 1/20 0.33
S1PR3 Q99500 1/20 0.33
S1PR5 Q9H228 1/20 0.33
NAAA Q02083 1/20 0.32
CCNT1 O60563 1/20 0.32
CDK9 P50750 1/20 0.32
FFAR4 Q5NUL3 9/20 0.32
MAPK1 P28482 1/20 0.31
KCNQ3 O43525 1/20 0.31
KCNQ2 O43526 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201234 0.91 PRMT6 (0.46) TRPV3PRMT6PRMT1PRMT8PRMT3
SCHEMBL16204239 0.89 PRMT1 (0.45) TRPV3PRMT6PRMT1PRMT8PRMT3
SCHEMBL16201443 0.87 PRMT6 (0.45) PRMT6PRMT1PRMT8S1PR1S1PR3
SCHEMBL16125845 0.86 CTSS (0.43) PRMT6PRMT1PRMT8PRMT3CARM1
SCHEMBL16201363 0.83 PRMT6 (0.39) TRPV3PRMT6PRMT1PRMT8PRMT3
SCHEMBL16125829 0.80 PRMT6 (0.43) PRMT6PRMT1PRMT8PRMT3CARM1
SCHEMBL16201289 0.80 PRMT6 (0.45) PRMT6PRMT1PRMT8PRMT3CARM1
SCHEMBL16201340 0.79 TDO2 (0.33)
SCHEMBL16201371 0.77 NPSR1 (0.39) PRMT6PRMT1PRMT8PRMT3CARM1
SCHEMBL16201384 0.76 PRMT3 (0.40) PRMT6PRMT1PRMT8PRMT3CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 TRPV3 4840/4885PRMT6 4/4885PRMT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.